A prospective, claims‐based assessment of the risk of pancreatitis and pancreatic cancer with liraglutide compared to other antidiabetic drugs
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Aim: We evaluated the relationship between liraglutide and acute pancreatitis or pancreatic cancer in an ongoing post‐marketing safety assessment programme. Methods: Initiators of liraglutide, exenatide, metformin, pioglitazone or groups containing initiators of dipeptidyl peptidase‐4 inhibitors or sulfonylureas were identified in a US commercial health insurance claims database (1 February 2010 to 31 March 2013) and followed for a median of 15 months. We estimated incidence rates ( IR /100 000 person‐years), rate ratio ( RR ) and 95% confidence intervals ( CI ) of new insurance claims with diagnoses of primary inpatient acute pancreatitis or pancreatic cancer from Poisson regression models. Results: The IR for acute pancreatitis for liraglutide was 187.5 compared with 154.4 for all non‐glucagon‐like peptide‐1 ( GLP ‐1)‐based therapies (adjusted RR 1.10; CI 0.81–1.49). The IR for pancreatic cancer was 19.9 for liraglutide compared with 33.0 for all non‐ GLP ‐1‐based therapies (adjusted RR 0.65; 95% CI 0.26–1.60). Conclusion: We did not observe excess risk of either outcome associated with liraglutide relative to individual or pooled comparator drugs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies
Elashoff, M., Matveyenko, A. V., Gier, B., Elashoff, R., & Butler, P. C. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.02.018 · Cited by 944 · cited 1×
“Recent publications have questioned the pancreatic safety of other GLP-1 receptor agonists (GLP-1RAs) [1–5], thus we performed this interim analysis on acute pancreatitis and pancreatic cancer with liraglutide.”
BackgroundSingh, S., Chang, H.-Y., Richards, T. M., Weiner, J. P., Clark, J. M., & Segal, J. B. (2013) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2013.2720 · Cited by 467 · cited 1×
“Recent publications have questioned the pancreatic safety of other GLP-1 receptor agonists (GLP-1RAs) [1–5], thus we performed this interim analysis on acute pancreatitis and pancreatic cancer with liraglutide.”
BackgroundButler, A. E., Campbell-Thompson, M., Gurlo, T., Dawson, D. W., Atkinson, M., & Butler, P. C. (2013) · Diabetes · doi:10.2337/db12-1686 · Cited by 457
A Critical Analysis of the Clinical Use of Incretin-Based Therapies
Butler, P. C., Elashoff, M., Elashoff, R., & Gale, E. A. M. (2013) · Diabetes Care · doi:10.2337/dc12-2713 · Cited by 296
Gier, B., Matveyenko, A. V., Kirakossian, D., Dawson, D., Dry, S. M., & Butler, P. C. (2012) · Diabetes · doi:10.2337/db11-1109 · Cited by 255
Cited by
Filippatos, T. D., Panagiotopoulou, T. V., & Elisaf, M. S. (2014) · The Review of Diabetic Studies · Cited by 560
Current pharmacotherapy for obesity
Srivastava, G., & Apovian, C. M. (2018) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2017.122 · Cited by 397
Smits, M. M., & Van Raalte, D. H. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.645563 · Cited by 332
Monami, M., Nreu, B., Scatena, A., Cresci, B., Andreozzi, F., Sesti, G., & Mannucci, E. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12926 · Cited by 243
“75 52 280 70 0 0 0 0 1 0 Araki 2015 (14) Glargine 0.”
Incretin based drugs and the risk of pancreatic cancer: international multicentre cohort study
Azoulay, L., Filion, K. B., Platt, R. W., Dahl, M., Dormuth, C. R., Clemens, K. K., Durand, M., Juurlink, D. N., Targownik, L. E., Turin, T. C., et al. (2016) · BMJ · doi:10.1136/bmj.i581 · Cited by 120
Association Between Incretin-Based Drugs and the Risk of Acute Pancreatitis
Azoulay, L., Filion, K. B., Platt, R. W., Dahl, M., Dormuth, C. R., Clemens, K. K., Durand, M., Hu, N., Juurlink, D. N., Paterson, J. M., et al. (2016) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2016.1522 · Cited by 120
Nauck, M. A., Jensen, T. J., Rosenkilde, C., Calanna, S., Buse, J. B., & the LEADER Publication Committee on behalf of the LEADER Trial Investigators (2018) · Diabetes Care · doi:10.2337/dc17-1825 · Cited by 94
“insurance claims database study that compared liraglutide with non–GLP-1–based therapy (median follow-up 15 months) (22).”
BackgroundOverbeek, J. A., Bakker, M., van der Heijden, A. A. W. A., van Herk‐Sukel, M. P. P., Herings, R. M. C., & Nijpels, G. (2018) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3004 · Cited by 71
“The full texts of the remaining studies were evaluated for the inclusion and exclusion criteria, which resulted in a final inclusion of 25 studies.(2,3,17-39) For 4 studies, the authors were contacted, because the publications did not contain sufficient information regarding risk or variables needed to calculate the r…”
BackgroundNREU, B., DICEMBRINI, I., TINTI, F., MANNUCCI, E., & MONAMI, M. (2023) · Minerva Endocrinology · doi:10.23736/s2724-6507.20.03219-8 · Cited by 63
An Updated Review on Cancer Risk Associated with Incretin Mimetics and Enhancers
Tseng, C.-H., Lee, K.-Y., & Tseng, F.-H. (2015) · Journal of Environmental Science and Health, Part C · doi:10.1080/10590501.2015.1003496 · Cited by 49
“Funch and associates conducted a prospective, ongoing postmarketing safety surveillance in a US commercial health insurance claims database [114].”
BackgroundJensen, T. M., Saha, K., & Steinberg, W. M. (2015) · Diabetes Care · doi:10.2337/dc13-1210 · Cited by 48
Therapies for inter-relating diabetes and obesity – GLP-1 and obesity
Iepsen, E. W., Torekov, S. S., & Holst, J. J. (2014) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2014.965678 · Cited by 43
“However, numerous other database studies revealed no evidence of an increased risk for pancreatitis with either exenatide or liraglutide use [95,96].”
BackgroundExenatide use and incidence of pancreatic and thyroid cancer: A retrospective cohort study
Liang, C., Bertoia, M. L., Ding, Y., Clifford, C. R., Qiao, Q., Gagne, J. J., & Dore, D. D. (2019) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13597 · Cited by 35
Metadata
- Authors
- Funch, D., Gydesen, H., Tornøe, K., Major‐Pedersen, A., & Chan, K. A.
- Venue
- Diabetes, Obesity and Metabolism
- Publisher
- Wiley
- Published
- 2013-11-26
- Volume
- 16
- Issue
- 3
- Pages
- 273-275
- ISSN
- 1462-8902 (ISSN-L)
- 1463-1326
- OpenAlex
- W2061738696
- Cited by
- 81
- References
- 5
- FWCI
- 8.02
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.